to paclitaxel/carboplatin, prolongs survival in previously untreated patients with advanced non-small-cell lung cancer: preliminary results from the ECOG Lung Cancer: Secondary Analyses of the ECOG and PointBreak Trials. Eastern Cooperative Oncology Group (E) and PointBreak studies. ECOG demonstrated longer progression-free (PFS) and overall survival ( OS) with the addition of bevacizumab at a dose of 15 mg/m2.

Author: Kikus Shakashura
Country: Finland
Language: English (Spanish)
Genre: History
Published (Last): 7 August 2006
Pages: 149
PDF File Size: 19.62 Mb
ePub File Size: 7.52 Mb
ISBN: 707-2-45550-152-8
Downloads: 26181
Price: Free* [*Free Regsitration Required]
Uploader: Fenrilkree

In this meta-analysis, diminished activity of bevacizumab in older patients was not seen, while the single-trial sub-analysis of ECOG suggested no benefit for older patients. Attempts to increase the activity of chemotherapy in a non-selective manner have included the addition of monoclonal antibodies, in particular, antibodies directed against the epidermal growth factor receptor EGFR or against the vascular endothelial growth factor VEGF. While the authors down-weighted those studies to adjust for the double counting, it is not clear that this entirely corrects for the correlation and the variance fcog the estimate may still be underestimated.

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Outcomes for elderly, advanced-stage non-small-cell lung cancer patients treated ecof bevacizumab in combination with carboplatin and paclitaxel: Of interest, Zhu et al. A study of docetaxel with or without vandetanib showed a PFS benefit, whereas there was no significant difference in PFS with pemetrexed [ 2324 ].

Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Doublet platinum-based chemotherapy 4599 been accepted evidence-based therapy for the last two decades.

All the remaining authors have declared no conflicts of interest. Citing articles via Web of Science The primary end point was overall survival.

Its precise contribution to increasing survival remains unclear. The addition of bevacizumab to paclitaxel plus carboplatin in the treatment of selected patients with non-small-cell lung cancer has a significant survival benefit with the risk of increased treatment-related deaths.


Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. Rapid chemotherapy-induced actue endothelial progenitor cell mobilization: There were 15 treatment-related deaths in the chemotherapy-plus-bevacizumab group, including 5 from pulmonary hemorrhage. In fact, the median survival of For permissions, please email: Nevertheless, it suggests that the addition of bevacizumab to paclitaxel-based doublet chemotherapy since its approval in the United States has not led to improved survival data in this Medicare population.

The effect of bevacizumab on lower stage disease similarly remains unclear. Finally, predictive markers are needed.

Phase III study of carboplatin and paclitaxel alone or with sorafinib in advanced non-small-cell lung cancer. However, a search for reliable, predictive biomarkers allowing for patient selection continues [ 7 ]. As discussed earlier, the paper is also diminished by the fact that individual patient data were not utilized eco updates beyond those of the initial database were not carried out.

It has also been investigated in multiple other solid tumors and is part of standard therapy in colorectal cancer, gliomas and renal cell cancer. Maintenance pemetrexed significantly increased PFS and in early reporting showed a positive trend for survival. Bevacizumab’s interaction with docetaxel Taxotere or nab-paclitaxel is not well established in lung cancer and will be of interest.

Thus, the trial investigated the addition of bevacizumab to a sub-optimal efog base for its target patient population. The role of bevacizumab in the maintenance setting remains unclear.

Chemotherapy was administered every 3 weeks for six cycles, and bevacizumab was administered every 3 weeks until disease progression was evident or toxic effects were intolerable. When attempting to integrate bevacizumab with radiation complications included tracheoesophageal fistula with fatal hemoptysis and this approach is not being pursued. Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer.


However, this was not a randomized comparison and therefore, is subject to bias. The broad conclusion that bevacizumab can be added to doublet chemotherapy with a survival benefit seems exaggerated, given that only two specific doublets were examined, one in patients who would no longer be offered the drug i.

Related articles in Web of Science Google Scholar.

As mentioned above, any clinical interaction with gemcitabine is likely to be small. Synergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases. Two randomized phase II studies are also included in the meta-analysis and evaluated bevacizumab added to paclitaxel [ 1314 ]. N Engl J Med. This would tend to push both HRs toward one. Anti-angiogenic therapy continues to hold promise and clearly benefits some patients. The median survival was Of greater clinical interest has been the interaction of pemetrexed with bevacizumab.

Maintenance chemotherapy for advanced non-small cell lung cancer: Receive exclusive offers and updates from Oxford Academic. Subset analysis suggested that older patients derived no benefit from the addition of bevacizumab [ 10 ].

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Currently, ECOG is comparing maintenance bevacizumab with pemetrexed versus the combination and this study should establish the relative contributions of these two agents to improving survival [ 22 ].

Rates of clinically significant bleeding were 4. Palliative chemotherapy improves the quality of life and prolongs survival in patients with metastatic non-small-cell lung cancer NSCLC. Vandetanib plus docetaxel ceog docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer ZODIAC: This strategy has been only marginally successful.

Posted in Art